Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Jenkins' Retirement From US FDA Was Several Years In The Making

Dec 06 2016

• By Derrick Gingery

Related Content

FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

Sep 15 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs

Dec 05 2016

Will US FDA Wind Up With More Political Positions Under Trump?

Dec 04 2016

FDA's Buehler To Join Teva

Oct 12 2010

In Brief: OTC emergency eyewash meeting, FDA official to Perrigo, e-cigarette regulation urged, emerging markets key for J&J in OTC

Sep 23 2013

Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director

Nov 09 2016

Finally … Rachel Sherman Takes Califf's Old FDA Job

Sep 22 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed

Jun 20 2016

Related Companies

Merck & Co., Inc.

Sarepta Therapeutics, Inc.

Additional Topics

United States FDA Leadership Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window